<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874324</url>
  </required_header>
  <id_info>
    <org_study_id>WCK 2349/ P-I/ MD/ 08</org_study_id>
    <nct_id>NCT04874324</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349</brief_title>
  <official_title>Phase-I Double-blind, Randomized, Placebo-controlled Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349 Under Fasting Conditions in Adult Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is planned to assess the safety, tolerability and pharmacokinetic profile&#xD;
      of WCK 2349 in US subjects with selected ascending multiple doses of WCK 2349 and to compare&#xD;
      the safety, tolerability and pharmacokinetic data with the data observed in similar studies&#xD;
      conducted in India.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2011</start_date>
  <completion_date type="Actual">June 25, 2011</completion_date>
  <primary_completion_date type="Actual">May 4, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety &amp; tolerability of multiple doses of WCK 2349</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the pharmacokinetics of multiple doses of WCK 2349</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>WCK 2349</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WCK 2349 800mg, 1000mg, and 1200mg . 1 dose given orally twice daily at 12 hourly interval for five days.&#xD;
Dosage form : Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo administered as Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WCK 2349 Oral</intervention_name>
    <description>1 dose given orally twice daily at 12 hourly interval for five days.</description>
    <arm_group_label>WCK 2349</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oral</intervention_name>
    <description>Subjects will receive matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be healthy males or non-pregnant females&#xD;
&#xD;
          -  Have a Body Mass Index (BMI) between 18 and 32 (both inclusive), calculated as weight&#xD;
             in kg / height in m2&#xD;
&#xD;
          -  Have no significant diseases or clinically significant abnormal findings during&#xD;
             screening, medical history, physical examination, laboratory evaluations and ECG&#xD;
             recordings.&#xD;
&#xD;
          -  Should test negative for drugs of abuse and urine alcohol test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or idiosyncratic reaction to quinolones or any other related&#xD;
             drugs.&#xD;
&#xD;
          -  Any history or evidence of disease or condition which might compromise the&#xD;
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,&#xD;
             immunological, dermatological, gastrointestinal or any other body system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashima Bhatia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wockhardt Ltd</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

